Ananda Developments - Notice of General Meeting

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

 Notice of General Meeting

The Directors of Ananda Developments PLC are pleased to announce that, further to the announcement of 9 September 2024 regarding the Fundraise and Proposed Debt Capitalisation,  the Company is today posting a Notice of Meeting to Shareholders convening a General Meeting ("GM") of the Company to approve the Proposed Debt Capitalisation for 2.00 p.m. on 8^th October 2024.

The GM is to be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London EC3V 0HR, at which the following resolutions will be proposed:

Resolution 1 - Authority to allot shares; and

Resolution 2 - Disapplication of pre-emption rights.The passing of Resolution 1 will require the approval of Shareholders by way of a simple majority.  Resolution 2 will require the approval of a majority of not less than 75% of the votes cast by those entitled to vote.

Full details of the Notice of Meeting and the Proxy card will be available on the Company's website at: https://anandadevelopments.com/publications/

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 10.30a.m. on 9 September 2024.

To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:  

·      Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906

·      Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·      LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·      Twitter: https://twitter.com/AnandaPlc

·      Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

About Ananda Developments

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/7Pl43P